This article was originally published in The Rose Sheet
Executive SummarySales of the fine fragrance unit fell 1.9% to $224.9 mil. (CHF1=$.82) during the first quarter of 2005, hampered by "strong comparables, particularly in the specialty retail segment and several postponed launches," Givaudan announces. North American sales of the division were sluggish compared to last year, the company adds. Net sales in the quarter declined 4.7% to $550.6 mil., due in part to the streamlining of non-core ingredients, according to firm...
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.